Nonalcoholic fatty liver disease: from steatosis to cirrhosis.
Nonalcoholic steatohepatitis (NASH), the lynchpin between steatosis and cirrhosis in the spectrum of nonalcoholic fatty liver disorders (NAFLD), was barely recognized in 1981. NAFLD is now present in 17% to 33% of Americans, has a worldwide distribution, and parallels the frequency of central adiposity, obesity, insulin resistance, metabolic syndrome and type 2 diabetes. NASH could be present in one third of NAFLD cases. Age, activity of steatohepatitis, and established fibrosis predispose to cirrhosis, which has a 7- to 10-year liver-related mortality of 12% to 25%. Many cases of cryptogenic cirrhosis are likely endstage NASH. While endstage NAFLD currently accounts for 4% to 10% of liver transplants, this may soon rise. Pathogenic concepts for NAFLD/NASH must account for the strong links with overnutrition and underactivity, insulin resistance, and genetic factors. Lipotoxicity, oxidative stress, cytokines, and other proinflammatory mediators may each play a role in transition of steatosis to NASH. The present "gold standard" management of NASH is modest weight reduction, particularly correction of central obesity achieved by combining dietary measures with increased physical activity. Whether achieved by "lifestyle adjustment" or anti-obesity surgery, this improves insulin resistance and reverses steatosis, hepatocellular injury, inflammation, and fibrosis. The same potential for "unwinding" fibrotic NASH is indicated by studies of the peroxisome proliferation activator receptor (PPAR)-gamma agonist "glitazones," but these agents may improve liver disease at the expense of worsening obesity. Future challenges are to approach NAFLD as a preventive public health initiative and to motivate affected persons to adopt a healthier lifestyle.
Farrell
Geoffrey C
GC
The Storr Liver Unit, Westmead's Millennium Institute, University of Sydney at Westmead Hospital, Westmead, NSW, Australia. gfarrell@u.washington.edu
Larter
Claire Z
CZ
D000818:Animals; D001706:Biopsy; D006528:Carcinoma, Hepatocellular / Q000209:etiology; D003920:Diabetes Mellitus / Q000628:therapy; D005234:Fatty Liver / Q000150:complications / Q000453:epidemiology / Q000503:physiopathology*; D006801:Humans; D007333:Insulin Resistance / Q000502:physiology; D008019:Life Style; D008103:Liver Cirrhosis / Q000209:etiology / Q000473:pathology / Q000628:therapy; D008107:Liver Diseases / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000473:pathology; D008113:Liver Neoplasms / Q000209:etiology; D012307:Risk Factors; D014463:Ultrasonography